Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 USD | +5.71% | +4.16% | +55.29% |
28/06 | ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion | MT |
28/06 | EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.29% | 82Cr | |
+19.41% | 4.55TCr | |
-8.62% | 3.85TCr | |
+38.54% | 3.81TCr | |
+26.95% | 3.07TCr | |
-13.50% | 2.6TCr | |
+10.74% | 2.59TCr | |
+44.87% | 1.41TCr | |
+34.36% | 1.27TCr | |
-7.14% | 1.13TCr |
- Stock Market
- Equities
- SPRY Stock
- News ARS Pharmaceuticals, Inc.
- ARS Pharmaceuticals Likely to Get Approval for Epinephrine Nasal Spray in H2 2024, Wedbush Says